5-苯基-2-噻酚基硼酸 | 306934-95-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 5-苯基-2-噻酚基硼酸
• 中文别名: 5-苯基噻吩-2硼酸；(5-苯基噻吩-2-基)硼酸
• 英文名称: 2-phenylthiophen-5-ylboronic acid
• 英文别名: (5-phenylthiophen-2-yl)boronic acid；2-phenyl-5-thiopheneboronic acid；5-phenyl-2-thienylboronic acid；5-phenylthiophene-2-boronic acid
• CAS: 306934-95-2
• 化学式: C₁₀H₉BO₂S
• mdl: MFCD01114643
• 分子量: 204.057
• InChiKey: RBSMKSPHBJFXCJ-UHFFFAOYSA-N

物化性质

• 熔点：
  140 °C
• 沸点：
  412.9±47.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.66
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  68.7
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• 安全说明：
  S26,S36/37/39
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

SDS

Name:	5-phenyl-2-thienylboronic acid, 97% Material Safety Data Sheet
Synonym:
CAS:	306934-95-2

Section 1 - Chemical Product MSDS Name: 5-phenyl-2-thienylboronic acid, 97% Material Safety Data Sheet
Synonym:

---

SECTION 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
306934-95-2	5-Phenyl-2-thienylboronic acid	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

SECTION 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW Irritating to eyes, respiratory system and skin. Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

SECTION 4 - FIRST AID MEASURES
Eyes:
Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

SECTION 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

SECTION 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

SECTION 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Keep refrigerated. (Store below 4C/39F.) Store in a tightly closed container. Store in a dry area.

---

SECTION 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 306934-95-2: Personal Protective Equipment
Eyes:
Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES
Physical State: Solid
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 146 - 210 deg C(decom)
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H9BO2S
Molecular Weight: 204

---

SECTION 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of sulfur, carbon dioxide, borane, boron oxides.
Hazardous Polymerization: Has not been reported

---

SECTION 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 306934-95-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-Phenyl-2-thienylboronic acid - Not listed by ACGIH, IARC, or NTP.

---

SECTION 12 - ECOLOGICAL INFORMATION

---

SECTION 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations.

---

SECTION 14 - TRANSPORT INFORMATION IATA No information available. IMO No information available. RID/ADR No information available.

---

SECTION 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S 37/39 Wear suitable gloves and eye/face protection. WGK (Water Danger/Protection) CAS# 306934-95-2: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 306934-95-2 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 306934-95-2 is not listed on the TSCA inventory. It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
MSDS Creation Date: 4/03/2003 Revision #0 Date: Original. The information above is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes. In no way shall the company be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if the company has been advised of the possibility of such damages.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-苯基-2-噻酚基硼酸 在 potassium phosphate 、 溴苯 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.5h， 生成 2-苯基噻吩
  参考文献：
  名称：

  铃木-宫浦sp 2 –sp 2交叉偶联中的镍与钯：在可比的前催化剂/配体系统中进行的头对头研究

  摘要：

  Suzuki–Miyaura反应是sp 2 –sp 2的基石方法工业中的交叉耦合。为了降低成本和提高可持续性，已经做出了共同的努力以使得能够使用Ni催化来代替Pd。尽管取得了重大进展，但与Pd相比，Ni催化的Suzuki-Miyaura交叉偶联的配体开发仍不发达，因此，Ni催化过程的配体通常取自Pd舞台。在这项研究中，我们评估了以常见的双齿配体（dppf）为首对首形式使用相似的Ni和Pd预催化剂对联芳偶合的最常见类型的效果，建立了直接替代Pd的实际含义与Ni一起，并从机械角度确定这些观察的潜在起源。

  DOI：

  10.1039/c9ob00561g
• 作为产物：
  描述：

  Dimethoxy-(5-phenylthiophen-2-yl)borane 在 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 5-苯基-2-噻酚基硼酸
  参考文献：
  名称：

  WO2008/133459

  摘要：

  公开号：

文献信息

• 신규한 질소 함유 헤테로환 화합물 및 이를 이용한 유기 전자 소자
  申请人：LG CHEM, LTD. 주식회사 엘지화학(120010134563) Corp. No ▼ 110111-2207995BRN ▼107-81-98139

  公开号：KR101567610B1

  公开（公告）日：2015-11-09

  본 발명은 신규한 질소 함유 헤테로환 화합물 및 이를 이용한 유기 전자 소자를 제공한다. 본 발명에 따른 유기 전자 소자는 효율, 구동전압 및 수명 면에서 우수한 특성을 나타낸다.

  这项发明提供了一种新型的含氮杂环化合物以及利用它们制造的有机电子器件。根据这项发明，有机电子器件表现出优异的效率、驱动电压和寿命特性。
• Nitrogenous heterocyclic derivatives and medicine thereof
  申请人：Eisai Co., Ltd.

  公开号：US06352989B1

  公开（公告）日：2002-03-05

  The present invention provides a novel nitrogen-containing heterocyclic compound useful as a phosphodiesterase-4 inhibitor, and a medicament comprising the same. Further, the present invention provides a nitrogen-containing heterocyclic compound represented by the following formula, its salt or hydrates thereof, and a medicament comprising the same. wherein the ring A is an aromatic hydrocarbon ring which may have a heteroatom, the ring B represents (a) a saturated hydrocarbon ring, (b) an unsaturated hydrocarbon ring, (c) a saturated heterocyclic ring or (d) an unsaturated heterocyclic ring, all of which may have a substituent group.

  本发明提供了一种新型的含氮杂环化合物，该化合物作为磷酸二酯酶-4抑制剂是有用的，以及包含该化合物的药物。此外，本发明还提供了一种由下列公式表示的含氮杂环化合物，其盐或水合物，以及包含它们的药物。 其中，环A是可以含有杂原子的芳香烃环，环B代表（a）饱和烃环，（b）不饱和烃环，（c）饱和杂环或（d）不饱和杂环，所有这些都可能含有取代基团。
• Rhodium‐Catalyzed Synthesis of Chiral Monohydrosilanes by Intramolecular C−H Functionalization of Dihydrosilanes
  作者：Wenpeng Ma、Li‐Chuan Liu、Kun An、Tao He、Wei He

  DOI：10.1002/anie.202013041

  日期：2021.2.19

  The preparation of chiral monohydrosilanes remains a rarely achieved goal. To this end a Rh‐catalyzed desymmetrization of dihydrosilanes by way of intramolecular C(sp2)−H functionalization under simple and mild conditions has now been developed. This method provides easy access to a broad range of chiral monohydrosilanes in good yields with excellent enantioselectivities (up to >99 % ee). The resulting

  手性一氢硅烷的制备仍然很少实现。为此，目前已经开发了在简单温和条件下通过分子内C（sp 2）-H官能化进行Rh催化的二氢硅烷脱对称。此方法可轻松获得具有良好对映选择性（最高> 99％ee）的高收率的各种手性一氢硅烷。所得的单氢硅烷构成了获得立体硅化合物的良好平台，也是探测硅立体化学的有用化合物。
• Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation
  作者：Mingfeng Yu、Yi Long、Yuchao Yang、Manjun Li、Theodosia Teo、Benjamin Noll、Stephen Philip、Shudong Wang

  DOI：10.1016/j.ejmech.2021.113391

  日期：2021.6

  is viewed as a therapeutic target for the treatment of the disease. Accordingly, the search for small-molecule inhibitors of CDK8 is being intensified. Capitalising on our initial discovery of AU1-100, a potent CDK8 inhibitor yet with a limited degree of kinase selectivity, a structure-based optimisation was carried out, with a series of new multi-substituted pyridines rationally designed, chemically

  CDK8 在多种类型的人类癌症中失调，被视为治疗该疾病的治疗靶点。因此，正在加紧寻找 CDK8 的小分子抑制剂。利用我们最初发现的 AU1-100，一种有效的 CDK8 抑制剂，但激酶选择性有限，我们进行了基于结构的优化，对一系列新的多取代吡啶进行了合理设计、化学制备和生物学评估。这种努力最终确定了42，这是一种更有效的 CDK8 抑制剂，具有优异的运动学选择性和口服生物利用度。42抗增殖作用的机制对 MV4-11 细胞进行了研究，表明该化合物可以阻止 G1 细胞周期并引发细胞凋亡。估计42的肝毒性和心脏毒性的风险较低。这些发现值得进一步研究42作为靶向癌症治疗剂。
• Multicyclic amino acid derivatives and methods of their use
  申请人：Devasagayaraj Arokiasamy

  公开号：US20070191370A1

  公开（公告）日：2007-08-16

  Compounds of formulae I and II are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and manage serotonin-mediated diseases and disorders:

  公式I和II的化合物已被披露，以及包含它们的组合物和它们的使用方法，用于治疗、预防和管理与血清素介导的疾病和紊乱：